Surrozen (NASDAQ:SRZN – Get Free Report) and Spyre Therapeutics (NASDAQ:SYRE – Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability and earnings.
Profitability
This table compares Surrozen and Spyre Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Surrozen | -2,885.33% | N/A | -93.62% |
| Spyre Therapeutics | N/A | -30.74% | -22.23% |
Analyst Ratings
This is a summary of current ratings and recommmendations for Surrozen and Spyre Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Surrozen | 1 | 1 | 4 | 1 | 2.71 |
| Spyre Therapeutics | 1 | 1 | 12 | 1 | 2.87 |
Institutional & Insider Ownership
66.6% of Surrozen shares are held by institutional investors. Comparatively, 80.4% of Spyre Therapeutics shares are held by institutional investors. 31.7% of Surrozen shares are held by insiders. Comparatively, 15.7% of Spyre Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Risk & Volatility
Surrozen has a beta of 0.56, suggesting that its share price is 44% less volatile than the S&P 500. Comparatively, Spyre Therapeutics has a beta of 2.99, suggesting that its share price is 199% more volatile than the S&P 500.
Valuation & Earnings
This table compares Surrozen and Spyre Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Surrozen | $3.48 million | 55.21 | -$242.03 million | ($40.55) | -0.41 |
| Spyre Therapeutics | $890,000.00 | 8,917.51 | -$155.20 million | ($1.95) | -46.28 |
Spyre Therapeutics has lower revenue, but higher earnings than Surrozen. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks.
Summary
Spyre Therapeutics beats Surrozen on 9 of the 14 factors compared between the two stocks.
About Surrozen
Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.
About Spyre Therapeutics
Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.
Receive News & Ratings for Surrozen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surrozen and related companies with MarketBeat.com's FREE daily email newsletter.
